A complete blood count costs $401 at the average Florida hospital and $32 from Quest’s own consumer site. Same test, same analyzers, same company in many cases. The receipts were sitting in a peer-reviewed cost study; what they needed was someone willing to set them next to each other.

That came on Saturday in the form of a Reddit post on r/longevity. A guy was pitching his side project, dirtcheaplabs.com, which resells Quest tests at close to wholesale plus a ten-dollar draw fee. He described it as a passion project running on a B2B platform that gives him bulk pricing in exchange for a platform fee. He passes the discount through. The site is not a hack or a workaround. It is a thinner skin around a layer Quest already sells into, and the prices it surfaces are the prices the consumer-facing arms of the same labs charge directly. The interesting thing is not that the site exists. The interesting thing is the gap it makes visible.

The $401 figure is not anecdotal. Researchers writing in Cureus last year pulled the published cost data for 42 of the 43 eligible Florida hospitals and lined it up against the cash prices at Quest’s and LabCorp’s direct-to-consumer arms. For a CBC, the mean charge to an uninsured Florida hospital patient was $401. The mean consumer price for the same test, ordered online by the same patient, was $32. The paper found similar gaps across a basic metabolic panel, a lipid panel, A1c, vitamin D, and PSA. A metabolic profile, depending on the hospital’s chargemaster, ran from $13 to $2,943. PSA, depending on the insurer’s negotiated rate, ran from $7 to $440. The authors called the variation inexplicable when set against the actual cost of running the assay.

That is the polite framing.

The dominant story has always been that lab pricing is what it is: tests cost what insurance pays for them, give or take, and patients who think they’re seeing a bargain on the consumer side are mostly buying convenience or vanity panels. The receipts have stopped cooperating with that story. Quest itself runs the bypass route. QuestHealth lists a testosterone test at $69 plus a $6 physician-service fee, a comprehensive metabolic panel at $49, a basic STD panel at $149, an expanded STD panel at $282, all with no doctor visit required and an independent provider in the loop on Quest’s side. LabCorp’s OnDemand is the same machinery in a different brand. The Reddit project sits one layer further out, passing through a B2B account the way a small importer passes through a wholesale tier.

The bypass price isn’t the test’s underlying cost. Cureus is careful to note Medicaid sometimes reimburses below the consumer price. What the bypass price is, plainly, is what the test costs once the chargemaster, the network-rate negotiation, the billing department’s downstream coding, and the surprise out-of-network bill come off the top. JAMA Internal Medicine documented in 2021 that about one in seventeen commercially insured patients with outpatient lab work in 2018 walked away with an out-of-network lab charge they hadn’t agreed to, with the state-level service rate climbing as high as 26 percent in Michigan. The bill arrives weeks later, addressed to someone who thought they had gone in-network and stayed there.

In another publication this is where the column-inches go to a careful warning against direct-to-consumer testing. The warning is worth saying once and then moving on. A blood test ordered without a clinician reading it is a number returned without context, and abnormal numbers are not rare. Run a fourteen-analyte panel where each marker has a five-percent chance of drifting outside a reference range from normal variation alone, treat the markers as independent for the sake of illustration, and roughly half of asymptomatic adults will see something flagged. The slightly elevated liver enzyme that a family doctor would have shrugged at becomes a hepatology referral and an MRI. The cautionary tale most often cited on the genetic side: a 2018 follow-up at Ambry Genetics ran confirmatory tests on 49 patients referred after a direct-to-consumer raw-data finding and found that 40 percent of the harmful variants the consumer report had named were false positives. FDA review does not fully close that gap. The agency reviews moderate- and high-risk DTC tests with a medical purpose and leaves general-wellness tests alone; its attempt last year to bring laboratory-developed tests under premarket review was vacated on Loper Bright grounds by the Eastern District of Texas in March 2025, and the rule has been dead letter since.

The cascade argument cuts the other way too. The insurance-billed system that is supposed to be supplying the clinical context is the one charging $401 for a CBC and mailing a surprise out-of-network bill on the way out the door. Cascades of unnecessary follow-up testing are not a consumer-market problem; the literature on physician-ordered overuse is older, larger, and more expensive. What is different on the consumer side is who’s paying. The patient is paying with their own money, and own money has a way of focusing attention on whether the test was worth running.

The Reddit project won’t fix any of this. It is one guy passing through a bulk discount until the host platform changes its terms. The trend it sits inside is the story, and the shape of the trend is a tax revolt. People are routing around an opaque pricing system not because they have a better one, but because the one they have charges them twelve times the going rate for the privilege of a clean phlebotomy. When the cost of opting out drops to ten dollars and a drive to the nearest collection site, more people opt out. The market is not broken. It is doing exactly what a market with hidden prices does the moment somebody publishes the prices.

Sources

  1. Cureus – Cost Comparisons of Physician-Ordered Versus Direct-to-Consumer Laboratory Testing in Florida (2025)
  2. JAMA Internal Medicine – Frequency and Costs of Out-of-Network Bills for Outpatient Laboratory Services Among Privately Insured Patients (2021)
  3. Genetics in Medicine – False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing (Ambry Genetics, 2018)
  4. QuestHealth – Quest Diagnostics direct-to-consumer lab testing
  5. Sidley – FDA’s Laboratory-Developed Test Rule Struck Down in Major Test of Loper Bright (2025)